

IX BIOPHARMA LTD.

(Company Registration No. 200405621W)
(Incorporated in the Republic of Singapore)

ISSUE AND ALLOTMENT OF NEW SHARES PURSUANT TO IX PERFORMANCE SHARE PLAN

Unless otherwise defined, all terms not defined herein shall be as defined in the rules of the iX Performance Share Plan (the "iX PSP").

The Board of Directors (the "**Board**") of iX Biopharma Ltd. (the "**Company**") refers to the Company's announcement issued on 1 December 2023 and 14 February 2025 in relation to the grants of awards of ordinary shares pursuant to the iX PSP (the "**Grants**").

The Board wishes to announce that the Company has issued and allotted 1,708,334 new shares (the "**New Shares**") on 21 February 2025, pursuant to the vesting of 1,708,334 shares for the Grants.

No share was issued to a Director or controlling shareholder (and each of their associates).

The New Shares rank *pari passu* in all respects with the existing shares of the Company. The New Shares are expected to be listed and quoted on Catalist on or around 25 February 2025, and trading of the New Shares is expected to commence with effect from 9.00 a.m. on the same date.

Following the allotment and issuance of New Shares, the total number of issued shares of the Company has increased from 883,336,340 shares to 885,044,674 shares.

By Order of the Board

Gwendolin Lee Soo Fern/Lai Kuan Loong, Victor
Company Secretaries

21 February 2025

This announcement has been reviewed by the Company's sponsor, UOB Kay Hian Private Limited (the "Sponsor"). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this announcement, including correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Lance Tan, Senior Vice President at 8 Anthony Road, #01-01, Singapore 229957, telephone (65) 6590 6881.